





New Biomarker Class for Multiple Sclerosis

Precision Medicine in Brain Disease



Value Proposition

State-of-the-art diagnosis and monitoring in MS are expensive, invasive, and monitor late-stage damage from disease activity. With the **discovery** of a **new class of sugar-based, blood-borne biomarkers for multiple sclerosis (MS)**, **early** events in autoimmune disease become traceable by the presence of specific shedding patterns in biological fluids.

Prevalence of **autoimmunity is rising**, and with it a burgeoning market **value**. **Investment** in this technology will position the investor on the front-line of complementary diagnostics for streamlining drug development, identifying treatment responders, and improving patient care through **precision medicine**.

Business Opportunity

With an estimated market size of **25 billion USD** for therapeutics and **16 billion USD** for diagnostic tools alone, this technology could exploit both of these market values through **efficient drug development** internally and a **sellable product** for clinics.

We are currently seeking collaborators to include our technology in their drug development and clinical trials and with biobanks interested in MS. Secondly, we seek partnership for development of a sellable kit for delivery of our technology broadly. We have established collaborations presently that will see some goals achieved in the following two quarters. We envision expansion of this collaboration base. We are currently seeking partners for kit development. We expect this to be a 1-year process upon partnership due to our extension knowledge of the markers involved.

Technology Summary

We have proof-of-concept tested a class of non-protein, sugar-based soluble markers that are released into the **bloodstream** upon immune invasion into the brain. These signals can be easily tested at a **high-resolution** ensuring a **low-cost** determination of disease status. We envision these measurements to have proven value in **distinguishing patient subtypes** and **treatment responders**.

Development Phase

The current phase of the invention is expanding upon established patient proof-of-concept into MS subtyping and treatment response.

The inventors

Brian Della Valle, Ph. D. (60%)
Casper Hempel, Ph.D. (30%)
Agnete Larsen, MD, Ph.D. (10%)

Contact Information

Morten Holmager
TTO Manager
+45 93 50 87 18
holmager@au.dk

Seeking

- Licensee
- Partner/Research Collaboration

European Priority application filed December 2017. Co-owned by Aarhus University (70%) and DTU (30%).